Long-term survival of sorafenib-treated FLT3-ITD –positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD –positive AML relapsing after allo-SCT.

Source: European Journal of Cancer - October 18, 2017 Category: Cancer & Oncology Authors: S.K. Metzelder, T. Schroeder, M. L übbert, M. Ditschkowski, K. Götze, S. Scholl, R.G. Meyer, P. Dreger, N. Basara, M.F. Fey, H.R. Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe, E. Wollmer, J. Finke, A. Neubauer, A. Burchert Tags: Original Research Source Type: research